13/09/2022 (Agence Europe) – The European Commission granted conditional marketing authorisation for a new adapted SARS-CoV-2 vaccine on Monday 12 September. This follows the recommendation published the same day by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) (see EUROPE B13019A12) in favour of authorising this vaccine. This bivalent messenger RNA vaccine developed by Pfizer-BioNTech targets the BA.4 and BA.5 sub-variants of concern of...